Brainstorm Cell Therapeutics Inc. (BCLI)
NASDAQ: BCLI · IEX Real-Time Price · USD
0.346
-0.031 (-8.12%)
At close: Jul 19, 2024, 12:00 AM
0.370
+0.024 (6.84%)
Pre-market: Jul 22, 2024, 9:06 AM EDT
BCLI Employees
Brainstorm Cell Therapeutics had 29 employees as of December 31, 2023. The number of employees decreased by 14 or -32.56% compared to the previous year.
Employees
29
Change (1Y)
-14
Growth (1Y)
-32.56%
Revenue / Employee
n/a
Profits / Employee
-$535,655
Market Cap
27.56M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Evogene | 142 |
Enlivex Therapeutics | 71 |
Equillium | 44 |
Surrozen | 42 |
Acasti Pharma | 32 |
Daré Bioscience | 26 |
Longeveron | 24 |
Akari Therapeutics, | 12 |
BCLI News
- 21 days ago - BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program - PRNewsWire
- 25 days ago - BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering - PRNewsWire
- 26 days ago - BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial - PRNewsWire
- 4 weeks ago - BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer - PRNewsWire
- 5 weeks ago - BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation - PRNewsWire
- 2 months ago - BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn - PRNewsWire
- 2 months ago - BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn - PRNewsWire